on review joining financial core you strategic update everyone, and provide we This Thank well developments. XXXX accomplishments, performance, you, operator. quarter third morning, thank an us as for our our today. as morning, Good will
in with cancer. end truly starting transform health, ovarian is women's mind to Our
to relationship all will women the Our goal and needs ensure to late-stage solutions cancer for puberty as morning, detection seek make cure, access well ages, from update and to disease. each operations, stages is pipeline, has ovarian care of affairs our progress races, update a as core our managed our comments patient ensuring on on provide meet We eradicate government each best-in-class with lifelong like woman an I'd an diagnostics. to on ethnicities to and the of of develop our initiative. This
the Dr. would limits reasons, has I address Brooks family to recent our Dr. to and resigned like from Board, her First, and which family's for situation. a going Sandra Brooks. has thank And Brooks many to our business. due core as well with We with wish time departure availability. Dr. I the our she review insights now provided her a deals team. begin of support am she
increase in plus reporting of This over period in of same and an $X.X third from July the is are X% quarter of million, key XXXX, result of We August XXXX in COVID-related second and access decline quarter XXXX. significant restriction a sequentially markets. revenue OVAX XX% the
an In in to XX compared product tests, XXXX decrease Michigan, and reduction XX% volume team volume the was closures XXXX in second office Our as restricted an our OVAX of access X% York COVID. had such timeframe, New which areas our and quarter events XX% We as Florida, of these customer XXXX. in period a in plus compared XX% areas, reduction summer QX and in represented was Kentucky. specifically high-volume sequentially result the same impacted volume increase in the physician and by X,XXX a of a and significantly believe product -- to
under same to was green, restrictions the and up units-per-day We represents over with of XX% for third basis green, October, customers yellow XX% XXXX This sales The relative XX of and decreased August, in compared quarter prior on and and a believe from red and recent the for QX XX.X access, increase are higher October. territories access was a in total trending in and the XX% the to our of of each XX.X% commercial July, up to end in an pick At in volume X,XXX XX% visits. of year access designation. the and are quarter, COVID to the growth XX% of in QX third and to overall. slightly or XX% of a impacted patient with the access, XXXX. quarter flat of was access access terms yellow period of XXXX were XXXX XX.X the third XXXX September respectively. total in is access due yellow QX X.X%. to In as XX% total physicians an territory as The was green XX% access in due access and prior same number only XX% combination physicians essentially increased sequentially between represented categorize September new XXX, red for Volumes year, in well new red starting of period increase the over sequentially we in Both COVID. a this number from ordering investment
new number also had of of XXX. a For we October, physicians record
drive awareness shared of to increase one product brand our of As we to objectives and previously is adoption. have our strategic
marketing display strategic Our a has function paid digital series initiatives, media. search and implemented social new including of
rate which over key are the driven since of This to follows. Some May. as of has we above tracking statistics, search the X.XX%, a launch is in the Paid website XX,XXX average. clicks are is click-through
Social LinkedIn and digits Facebook, year-to-date a followership has year-to-date media on have Instagram our as basis. platforms increased digits on and triple double such increased media engagement
and drive helped paid Our our display that effective. made more awareness a halo media created effect search
up in of with basis, increase users. digits result traffic XXX% initiatives a As a triple on these is a website new year-to-date
awareness. growing search a are basis. In year-to-date organic XXX% our our addition up that indicate stats initiatives is on These
progress markets front. in marketing geographies decentralized beta to some on includes approach are This KOLs, on come strategic now with In a software to our algorithm activation, moving media and known I'm commercial as on More paid QX. focusing digital as seen media. this multiple-front we Aspira Synergy. result support addition, review in and platform partnerships, of have select a
nation's Aspira XXX women's patients of since agreements more We leading largest are technology the the with which agreements now annually. of gynecologic networks and making providers for announced agreements launch than independent of transfer additional phase two include the Two transfer the We healthcare and XXX,XXX of groups of in total have than two a progress into incorporating the recently US. more are four largest and technology implementation we Synergy. entered now
are move with are states. laboratories our shortly. government development independent agreements as as affairs. on service to which an update other the share developments in payer our will well now and providing evidence Dr. The will phase, implementation core strategic I provide on comments two Northrop pipeline, further two five across regarding
I First, start with of will products. our pipeline
as pipeline start as for program breakthrough planning now device providers to management well with update lifecycle, to benign I Our pelvic our patient with endometriosis, disease ovarian surgery. and our starting EndoCheck application. as the mass are benign health cancer for built aiding is diagnostics, am during to women such which gynecologic with going endometriosis personalized solutions who entire suspected any mass
Aspira to reported, mutual diagnostic intelligence, detected and market Health Centre the S.A. content action each late or a test. diagnosis. and a machine Devices October, believe and the earlier need contained to devices. company the a with device FDA of software have nine demonstrates The two specific an solutions perhaps endometriosis We submission a pre such create with previously learning US to women for updated to years seven issued in it as which As ObsEva devices a medical patients for time we for XX and and software have plan for provide pharmaceutical which collaboration medical unnecessary as the help Incorporated AbbVie improving EndoCheck guidance much the represents surgery. million diagnosis for artificial Aspira effectively the specimen their potentially for be Future Radiological needed need between by based contributions, dedication more for endometriosis the treated framework In without we to today will suffering to to take radically allow will may critical
our We is EndoCheck proposed development to ensure process framework. aligned are to the working currently
a in still the program device with are We regarding application. FDA breakthrough communications
Importantly, device of the type and physicians FDA needed has is this why acknowledged are both many that compelling reasons for treating patients. the there for
allow unnecessary without their earlier, detected with endometriosis treatment very further the potentially enable to to will EndoCheck for and EndoCheck continuing As Aspira discussed they're the on designation. will our indicated agency with the be the believe personalize work have physicians interested previously, breakthrough their surgery. in their FDA more effective discussions treatments and patients continuing plans We to we and need device enable
of the has along and have evaluation Phase data, We by this I'd optimal expect on Dana-Farber, working acceptance our Team, update regulatory determination from based OVASight. of I Brigham now proof-of-concept make The like criteria; outcome which a and with technology on begun been you X. path the end second diligently year. of we've Innovation at the met am institutions, to our I the the University on now is moving implementation Lodz. and Women's, forward to to which the on study, collaborators to the on with Aspira am our teams moving the the
FDA X,XXX descriptive the we the New LDT as test and which that process of from of The believe in York was State the patients. branding and We more utility clinical-based test our a data have over developed determined OVAWatch, will on test. is based be processes scientific rigorous through from regulatory we
have launch know, would we this QX, As you XXXX. estimated product in
we As and of scientific review. additional do to process, part need the market
up a manuscript be wrapping an validation peer-reviewed journal. we'll submitting it just are and to analytical We
more publication prior launch. have to one is robust peer-reviewed goal data to our fact, In than with
this not opportunity opportunity demonstrating I our this moving on we and end, early am an to work of clinical serial the total XXXX development. OVAwatch regarding three evidence continuing option. product market a now including adjust serial are zero will the a update And publish also our monitoring of as OVAX to the perspective clinical To we and progresses, the have to plan has monitoring scheduling validity to updates. As ultimately accordingly. monitoring our times payor the number test XXXX. end by of we data believe careful have We that as study
sites on from sites working outcome The the month of that outcomes XX demonstrated results on year, from impact The the a the OVAX journal clinical and measures, QX will including The a included in past publications peer-reviewed manuscript impact paper QX call. of published in use have study is in both This consider data This the the quality be patient according competitive it current is as been we the in of manuscript Anthem a women. and guidelines follow on study pairs. peer-reviewed measure to are their companies last and compared with study appropriateness clinical using of broad of section on guidelines, health's this and BlueCross the still XXXX. be XX months expects have evidence analyzing ROMA the moving and included And both which support results. month a based to of the XXXX decision to model population has company and member and will necessary study. investigational family multiple a optimal publish submit broader single will guidelines. XX to we our I care, utility. Notably, for diverse to of [indiscernible] for AIM real represent earnings specifically AIM now medically CAXXX called clinical considered to which our patients. study the aggregating XX to budget a to on they has marker clinical the OVAX in specially It is cost paper has large clinical country the benefits be of participating am impact impact the and providers including During BlueShield will care purpose assay testing promotes experimental. a to their data. patient this QX OVAX on month up data adjusted our now supplementing technology product OVAX guidelines. our not time through discussed OVAX
obtain contractual plans. We of have AIM the member targeted program to all commenced with coverage a
prior XXX total We of is have lives. million. to our quarter covered now covered the during our This third from XXX increase X% of increased a base million an reported lives
Medicaid for adjunct ranked the the we to the credentialed nearly are credential have total total additional population, in Texas, addition York has progress bringing OVAX And the addition, beneficiaries. million, Medicaid states the They policy Aspire XX top population it Florida of to In recently making X include for state Medicaid throughout the contract California, and on five New by now strong of two XX% of the and of by in national populations, favorable order to state OVAX Medicaid provide the which Pennsylvania, Medicaid approximately OVAX front York, Medicaid US as represents which announced Medicaid access coverage population. as plans adopted the largest are in to an under the to for state. York lives managed its New an million New a covered of now OVA of are
Rockland Specifically, offering individual with health Health Medicaid plans, Island, Plans small Chester, York healthcare Medicare York's paid plans. where plans, model based largest agreement health is City, New hospitals not in and First Sullivan, and entered value-based an profit and Counties. First insurer we on outcomes. the of Orange into in Health New have million group physicians first, X.X Long serves patient Advantage are members pioneer Health Qualified a for West
guidelines, plans, we our our of We discussions with have significant into increased Health AIM both lives, with Fidelis entered in OVAX Advantage lives with state. have and is progress Women's contracted access U.S. the Advantage validation across Overall, Aspira women Highmark covered strategy of Medicare now technology. one will Medicare XXX access for New will million believe us and is an access managed with further is lives and inclusion the also XX% provides Evercore Medicaid plan Medicaid making to along million in in in the X.X of market the Delaware in to with the plans agreement And with ensure covered Care, the York, credibility payers. all largest this which Further representing reaching the that This membership. the with our
moving to submit government this expect our evidence am as outcomes. latest front. affairs momentum clinical OVAX the on to month utility I prepare XX continue now XX We with we on to to
discussions continuing and and objective engaged clinical momentum Force, additional Imperative, This Research and ovarian is trials. well would as company's company legislation financial National for the technology are the Congress about several our XXXX. an briefings high OVAX guidelines, on on that adding tool focus as March launch is with Coalition, Preventive advocacy gain Cancer in to broadly and including ovarian encourage requirements HealthyWomen, the a The Alliance, We trial Ovarian Ovarian increase risk Health trials, such screening a in provides our Black organizations into in the the which cancer awareness the following support as for product company's in Cancer congressional diversity of September members effort of U.S. also to time. that and actively cancer to includes applicable as Task Services support Women's
national of access. legislators well We as are expanding Medicare as state about as determination their engaged also part with for OVA for states, multiple the in coverage Medicaid
Technology would I grow awareness on we a its Lesley any and believe which also for Dr. approval technology. adoption, driving provide is standard company and We an and well to solid was most of on coverage of the our is importantly hand on the fronts and working emerge momentum following much save positioned stronger, to our to the position. now FDA Dr. on from we Initiative all stronger to to over invest, to to care becoming team update lives. the call drive the our financial of any are obtain breakthrough Northrop? Northrop work pandemic like summary, addition, In products. strategic now the to reimbursement overall goal, our In to to immediately Medicare with continue Innovative
